目的：探讨动态增强磁共振成像（DCE-MRI）各参数与人乳房珠蛋白（hMAM）、Ki67表达的关系及其临床诊断价值。方法：选取我院收治的80例女性乳腺疾病患者作为研究对象，采用DCE-MRI对患者进行扫描检查，检测病灶组织中hMAM及Ki-67水平，分析DCE-MRI各参数与hMAM、Ki67表达的关系及其临床诊断价值。结果：良性病变组病灶组织hMAM及Ki-67阳性表达量显著低于恶性肿瘤组（P<0.05），患者早期增强率（EER）、最大线性斜率（Slope）、MIP图血管计数（NTV）水平显著低于恶性肿瘤组（P<0.05），强化峰值（SI_max）、达峰时间（T_peak）及表观弥散系数（ADC）水平显著高于恶性肿瘤组（P<0.05）；EER、T_peak、NTV及ADC与组织hMAM及Ki-67水平显著相关（P<0.05）；DCE-MRI诊断特异度为92.31%，诊断准确率为87.50%。结论：乳腺癌患者DCE-MRI扫描各参数与hMAM、Ki67表达水平密切相关，且具有较高的临床诊断价值。

[1] PICKLES M D,LOWRY M,MANTON D J,et al.Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy:a comparison with traditional survival indicators[J].Eur Radiol,2015,25(4):1097.
[2] MIN J K,SU M Y,YU H J,et al.US-localized diffuse optical tomography in breast cancer:comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers[J].BMC Cancer,2016,16(1):1-9.
[3] 印滇,王亚非,杨莉,等.hMAM水平与乳腺癌早期诊断和癌微转移的相关性及临床意义研究[J].临床和实验医学杂志,2015(18):1512-1515.
[4] KIM T H,KANG D K.Is there any correlation between model-based and model-free parameters on DCE-MRI in breast cancer patients?[J].Apmis,2015,123(9):759-764.
[5] 张彦收,唐甜甜,周涛,等.Ki-67表达水平检测在乳腺癌新辅助化疗疗效评估中的价值[J].现代肿瘤医学,2017,25(14):2256-2259.
[6] YI A Y,HUN K S,KANG B J,et al.Treatment response evaluation of breast cancer after neoadjuvant chemotherapy and usefulness of the imaging parameters of MRI and PET/CT[J].J Korean Med Sci,2015,30(6):808-815.
[7] KING A D,CHOW S K K,YU K H,et al.DCE-MRI for pre-treatment prediction and post-treatment assessment of treatment response in sites of squamous cell carcinoma in the head and neck[J].PLoS One,2015,10(12):e0144770.
[8] 张书勤,马薇.富含半胱氨酸的分泌性酸性蛋白在乳腺癌组织中的表达及其临床意义[J].中国妇幼保健,2016,31(23):5157-5159.
[9] ALINA T,OH K Y,Y C C S,et al.Early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy using quantitative DCE-MRI[J].Transl Oncol,2016,9(1):8.
[10] 王晓刚,陈振文,郗彦凤,等.人表皮生长因子受体2蛋白过表达及基因异常在非小细胞肺癌中的临床意义[J].肿瘤研究与临床,2016,28(1):21-27.
[11] FAN M,LI H,WANG S,et al.Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer[J].PLoS One,2017,12(2):e0171683.
[12] DRISIS S,METENS T,IGNATIADIS M,et al.Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer:the impact of breast cancer subtypes on the diagnostic accuracy[J].Eur Radiol,2015,26(5):1474-1484.
[13] 谢玲,陈劼,孙怡,等.中国结直肠癌、肺癌和胃癌患者KRAS基因突变情况分析[J].临床与实验病理学杂志,2016,32(2):210-213.
[14] 卫文俊,陶霖玉,齐柯,等.钼靶下导丝定位活检在诊断触诊阴性乳腺病灶中的应用[J].东南大学学报(医学版),2013,32(5):559-562.
[15] KIM T H,YOON J K,KANG D K,et al.Correlation between F-18 fluorodeoxyglucose positron emission tomography metabolic parameters and dynamic contrast-enhanced MRI-derived perfusion data in patients with invasive ductal breast carcinoma[J].Ann Surg Oncol,2015,22(12):3866-3872.